(S (PP (IN With) (NP (NP (DT an) (JJ estimated) (CD 160,000) (NNS deaths)) (PP (IN in) (NP (CD 2018))))) (, ,) (NP (NN lung) (NN cancer)) (VP (VBZ is) (NP (NP (DT the) (ADJP (RBS most) (JJ common)) (NN cause)) (PP (IN of) (NP (NN cancer) (NN death))) (PP (IN in) (NP (DT the) (NNP United) (NNPS States))))) (. .))
(S (NP (NNP Lung) (NN cancer) (NNP CT) (NN screening)) (VP (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB reduce) (NP (NN mortality)) (PP (IN by) (NP (QP (IN up) (TO to) (CD 40)) (NN %))))))))) (CC and) (VP (VBZ is) (ADVP (RB now)) (VP (VBN included) (PP (IN in) (NP (NNP US) (VBG screening) (NNS guidelines)))))) (. .))
(S (S (VP (VBG Reducing) (NP (NP (DT the) (JJ high) (NN error) (NNS rates)) (PP (IN in) (NP (NN lung) (NN cancer) (NN screening)))))) (VP (VBZ is) (ADJP (JJ imperative)) (PP (IN because) (IN of) (NP (NP (DT the) (JJ high) (ADJP (JJ clinical) (CC and) (JJ financial)) (NNS costs)) (VP (VBN caused) (PP (IN by) (NP (NN diagnosis) (NNS mistakes))))))) (. .))
(S (PP (IN Despite) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NP (NNS standards)) (PP (IN for) (NP (JJ radiological) (NN diagnosis))))))) (, ,) (NP (NP (JJ persistent) (JJ inter-grader) (NN variability)) (CC and) (NP (NP (JJ incomplete) (NN characterization)) (PP (IN of) (NP (JJ comprehensive) (NN imaging) (NNS findings))))) (VP (VBP remain) (PP (IN as) (NP (NP (NNS limitations)) (PP (IN of) (NP (JJ current) (NNS methods)))))) (. .))
(S (NP (DT These) (NNS limitations)) (VP (VBP suggest) (NP (NNS opportunities) (SBAR (IN for) (S (NP (ADJP (RBR more) (JJ sophisticated)) (NNS systems)) (VP (TO to) (VP (VB improve) (NP (NP (NN performance)) (CC and) (NP (JJ inter-reader) (NN consistency))))))))) (. .))
(S (PP (IN In) (NP (DT this) (NN report))) (, ,) (NP (PRP we)) (VP (VBP reproduce) (NP (NP (DT a) (JJ state-of-the-art) (JJ deep) (NN learning) (NN algorithm)) (PP (IN for) (NP (NN lung) (NN cancer) (NN risk) (NN prediction))))) (. .))
(S (NP (PRP$ Our) (NN model)) (VP (VBZ predicts) (NP (NP (NP (NN malignancy) (NN probability)) (CC and) (NP (NN risk) (NN bucket) (NN classification))) (PP (IN from) (NP (NN lung) (NNP CT) (NNS studies))))) (. .))
(S (NP (DT This)) (VP (VP (VBZ allows) (PP (IN for) (NP (NP (NN risk) (NN categorization)) (PP (IN of) (NP (NP (NNS patients)) (VP (VBG being) (VP (VBN screened)))))))) (CC and) (VP (VBZ suggests) (NP (DT the) (ADJP (RBS most) (JJ appropriate)) (NN surveillance) (CC and) (NN management)))) (. .))
(S (S (VP (VBG Combining) (NP (PRP$ our) (NN solution)) (NP (NP (JJ high) (NN accuracy)) (, ,) (NX (NN consistency)) (CC and) (NX (ADJP (RB fully) (JJ automated)) (NN nature))))) (, ,) (NP (PRP$ our) (NN approach)) (VP (MD may) (VP (VP (VB enable) (NP (ADJP (RB highly) (JJ efficient)) (NN screening) (NNS procedures))) (CC and) (VP (VB accelerate) (NP (NP (DT the) (NN adoption)) (PP (IN of) (NP (NN lung) (NN cancer) (NN screening))))))) (. .))
